Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

This is further to the Press Release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised Press Release.
15-12-2023
Bigul

Cipla ups investment in GoApptiv, its third in the digi-tech company

This move aligns with Cipla's strategy to address critical healthcare gaps through technology-driven advancements.
15-12-2023
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Acquisition of additional stake in GoApptiv Private Limited.
14-12-2023
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Acquisition

Cipla Limited has entered into definitive agreements on 14th December 2023 to acquire additional stake in GoApptiv Private Limited.
14-12-2023
Bigul

CIPLA LTD. - 500087 - Cessation Of Facility Demand Guarantee Issued In Favor Of First Rand Bank, South Africa

Cessation of Facility Demand Guarantee issued in favor of First Rand Bank, South Africa
13-12-2023

Cipla Share Price Live blog for 11 Dec 2023

Cipla stock price went down today, 11 Dec 2023, by -1.25 %. The stock closed at 1219.35 per share. The stock is currently trading at 1204.05 per share. Investors should monitor Cipla stock price closely in the coming days and weeks to see how it reacts to the news.
11-12-2023

Cipla's US-arm recalls drug due to improper seal, could have life threatening' effects; shares fall

The product, Vigabatrin for oral solution, USP 500mg, is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older.
11-12-2023
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release - Voluntary Nationwide Recall of one lot of Vigabatrin for Oral Solution, USP 500 mg due to leaking sachets by InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company in USA.
10-12-2023
Bigul

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
09-12-2023
Bigul

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
07-12-2023
Next Page
Close

Let's Open Free Demat Account